With respect to the SARS-CoV-2 pneumonia, review of literature reveals the prevalence of pleural effusion can be as high as 14% in patients.3–5 In one of the largest trials, Li et al.3 described intrathoracic lymph node enlargement in 67% of cases and pleural effusion in 14% of cases. Patients with more severe cases have a higher prevalence of both lymphadenopathy and pleural effusions.3–5